Patterns of Statin Utilization
and persistence on statin therapy after reinitiation among United States Medicare beneficiaries after hospital discharge for a MI.
Methods

Study Population
The current analysis is a retrospective cohort study of Medicare beneficiaries with a hospitalization for MI between January 1, 2007, and December 31, 2012, who had Medicare fee-for-service and pharmacy coverage at the time of the event (n=918 464). MI hospitalizations were identified using the International Classification of Disease, Ninth Edition coding system (410.xx in any discharge diagnosis position except 410.x2, which indicates a subsequent episode of care) from Medicare Part A inpatient claims. 11 Analyses were restricted to beneficiaries with consistent demographic information who were ≥66 (to permit a 1-year baseline period to assess covariates) and ≤110 years of age and had continuous Medicare Part A (in-hospital), Part B (outpatient), and Part D (pharmacy) coverage without Part C (Medicare Advantage) from 365 days prior to the MI hospitalization admission date through 730 days after hospital discharge ( Figure 1 ). Additionally, we required that beneficiaries filled a statin in the 30 days after discharge, lived in the United States from 365 days prior to admission to 730 days post-discharge, and did not have hospice care from 365 days prior to their MI hospitalization to 730 days postdischarge or skilled nursing facility care from MI hospitalization to 730 days post-discharge because there are gaps in the prescription claims during periods of skilled nursing and hospice benefits. An index MI hospitalization was defined as the first eligible inpatient MI hospitalization claim for each individual. After these criteria were applied, the final study population included 158 795 beneficiaries. Follow-up ended on December 31, 2014. The University of Alabama at Birmingham Institutional Review Board governing human subjects' research and the Centers for Medicare and Medicaid Services Privacy Board approved the study.
Exposures
Medicare beneficiaries' information on demographics (age, race/ethnicity, sex, low income subsidy, area-level median income, geographic region), characteristics prior to the MI hospitalization (cardiologist care, diabetes mellitus, stroke, chronic kidney disease [CKD] , heart failure [HF], CHD, statin use, and nonstatin lipid-lowering medication use), characteristics during the MI hospitalization (length of hospitalization, coronary stent insertion, newly diagnosed HF, diabetes mellitus, and CKD), characteristics after the MI hospitalization (statin intensity filled and statin intolerance), and the index hospitalization admission and discharge dates were assessed using enrollment and claims data.
Age at the time of index MI hospitalization discharge was categorized as 66 to 69, 70 to 74, 75 to 79, 80 to 84, and ≥85 years old. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, Hispanic, Asian, and other. Low-income status was defined by presence of a low-income subsidy for Part D, state buy-in entitlement, or dual Medicare/Medicaid eligibility in the 365-day baseline period or 182 days after hospital discharge. Area-level median income, derived from zip codes linked to US Census data, was categorized into quartiles. Cardiologist care was defined by having a claim for visiting a cardiologist (provider specialty code 06 linked to a physician evaluation and management code). Geographic region was defined according to US Census categories. Diabetes mellitus, stroke, CKD, HF, and CHD prior to the MI hospitalization were defined as having diagnosis codes for these health problems on claims filed in the 365 days before the admission date. New diagnoses of diabetes mellitus, CKD, and HF, defined as having a diagnosis code for these health problems on the same claim as the index MI hospitalization, were determined among beneficiaries without prior evidence of each specified condition. Statin and nonstatin lipid-lowering medication fills were identified in Medicare Part D claims. Length of hospitalization was calculated as the difference in days between the hospital discharge and admission dates. Statin intolerance was defined using a previously described algorithm. 12 Statin intensity was categorized as low, moderate, and high, consistent with the 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. 4 Table I in the Data Supplement reports statin intensity equivalents. We categorized statin intensity using the last statin prescription filled during the 6-month period after discharge. For beneficiaries who discontinued statin use, we categorized statin intensity using the last statin filled prior to discontinuation. Statin intensity was also determined at the time of statin reinitiation.
Medication Discontinuation, Reinitiation, and Persistence
Beneficiaries who filled a statin within 30 days of a hospital discharge for MI (Figure 2 , left panel) were followed to identify discontinuation within 182 days of the discharge date ( Figure 2 , center left panel). Discontinuation of statin therapy was defined as having a 60-day continuous period with no statin supply after the initial post-discharge statin fill. The statin discontinuation date was the date that a beneficiary had 60 continuous days with no days of statin supply. Any statin doses remaining from a fill prior to hospital admission were carried into the time period post-discharge. Additionally, if statin supply was remaining when a statin prescription was refilled, the existing statin supply was augmented by the new statin fill.
Statin reinitiation was evaluated during the 365 days after the statin discontinuation date (Figure 2 , center right panel). Beneficiaries who had a Part D claim for a statin were categorized as having reinitiated statins. Change in statin type and intensity on reinitiation were defined by comparing the last statin filled prior to discontinuation, with the statin filled on reinitiation (eg, switching from simvastatin to atorvastatin or from atorvastatin 80 mg to 20 mg). High statin persistence was defined as a proportion of days covered ≥80% during the 182 days after reinitiation and having at least 1-day supply of statin on day 182 post-reinitiation ( Figure 2 , right panel). Figure I in the Data Supplement provides examples that demonstrate the trajectory of a hypothetical beneficiary who discontinued a statin and did not reinitiate treatment and a second hypothetical beneficiary who discontinued a statin followed by treatment reinitiation with high statin persistence.
Statistical Analysis
Descriptive statistics for beneficiary characteristics were calculated overall and by history of statin use prior to the MI
WHAT IS KNOWN
• Although statins reduce the risk of cardiovascular disease, discontinuation of statin therapy is common.
WHAT THE STUDY ADDS
• Among Medicare beneficiaries, 15.4% discontinued statin treatment within 6 months of discharge for myocardial infarction.
• Approximately half of Medicare beneficiaries reinitiated statin therapy within a year of discontinuation.
• Less than half of Medicare beneficiaries had high statin persistence over the 6 months after reinitiation.
• Reinitiating therapy with moderate-or low-intensity statins, down-titration, and changing statins may promote persistence in older adults who discontinue statins. Patterns of Statin Utilization hospitalization and separately by statin discontinuation, reinitiation, and persistence status, overall, and by history of statin use. Analyses described hereafter were performed in the overall sample and subgroups defined by history of statin use prior to the index MI hospitalization. The percentage of Medicare beneficiaries filling a statin within 30 days of the index MI hospital discharge was calculated. Among beneficiaries who filled a statin, the percentage discontinuing treatment within 182 days after hospital discharge for their index MI was calculated. Next, the proportion who reinitiated statins within 365 days after discontinuation was determined. Among those who reinitiated treatment, the percentage of beneficiaries reinitiating the same statin drug type and intensity compared with the last statin filled prior to discontinuation was calculated. The percentage of beneficiaries with high statin persistence for 182 days after reinitiation was also calculated. The number of beneficiaries included in the statin discontinuation, reinitiation, and persistence analyses is shown in Figure 2 .
Poisson regression with robust variance estimates was used to calculate the relative risk and 95% confidence interval (CI) for (1) statin discontinuation within 182 days post-discharge associated with moderate-and high-versus low-intensity statins (the last statin filled prior to discontinuation or the last statin filled in the 182 days after the index MI hospital discharge for beneficiaries who did not discontinue treatment), and (2) high statin persistence associated with statin intensity reinitiated (moderate-and high-versus low-intensity), statin intensity change (up-titration and down-titration versus no change), and statin drug type change (yes versus no) on reinitiation. 13 Additionally, we calculated relative risks for statin discontinuation, reinitiation, and high persistence associated with patient characteristics prior to, during, and after the MI hospitalization (described above). Models included all characteristics simultaneously (ie, age, race/ethnicity, sex, The 365 days opportunity for statin reinitiation begins on the first day after 60 days with no supply of statin.
‡ The proportion of days covered ≥80% during the 182 days after reinitiation and having at least 1-day supply of statin on day 182 post-reinitiation. 
Results
Beneficiary Characteristics
Beneficiaries were on average 75.9 years old, 85.8% were nonHispanic white, and 47.7% were men (Table 1) . Prior to the MI hospitalization, 34.6% of beneficiaries had a history of diabetes mellitus and 48.5% had a history of CHD. Statin and nonstatin lipid-lowering medications were used prior to the MI hospitalization by 54.5% and 14.3% of beneficiaries, respectively. The median length of MI hospitalization was 5 days. Compared with beneficiaries without a history of statin use prior to their MI, those with a history of statin use were more likely to be from a race/ethnicity other than non-Hispanic white, have cardiologist care, diabetes mellitus, stroke, CKD, HF, CHD, and to be taking a nonstatin lipid-lowering medication prior to MI hospitalization, and less likely to have a coronary stent insertion and newly diagnosed diabetes mellitus during the MI hospitalization. The characteristics of beneficiaries by statin discontinuation, reinitiation, and high persistence status overall and in subgroups defined by statin use prior to index MI hospitalization are shown in Tables II through IV in the Data Supplement. Figure 3B ) compared with those with a history of statin use prior to their index MI (10.9%; P<0.001; Figure 3C ). Reinitiation was less common among those who did not have a history of statin use compared with those with a history of statin use (42.9% versus 70.8%, respectively; P=0.04). On reinitiation, beneficiaries who did not have a history of statin use were less likely to reinitiate the same drug and to be highly persistent and more likely to down-titrate compared with beneficiaries with a history of statin use prior to their MI (each P<0.001).
Patterns of Statin Discontinuation, Reinitiation, and Persistence
Statin Intensity and Discontinuation
Overall, statin discontinuation occurred within 182 days postdischarge among 2192 (17.4%) of the beneficiaries taking a low-intensity and 15 254 (15.3%) and 7015 (15.0%) of those taking moderate-and high-intensity therapy, respectively ( Table 2) . Use of moderate-and high-compared with lowintensity statins was associated with less statin discontinuation, overall, and among beneficiaries without history of statin use after multivariable adjustment. Among beneficiaries with a history of statin use, moderate-and high-versus low-intensity statins were not associated with discontinuation. 
Statin Intensity and Drug Reinitiated and High Persistence
The number and percentage of beneficiaries who were taking low-, moderate-, and high-intensity statins and the percentage who changed statin intensity and who changed statin drug type on reinitiation is shown in Table 3 , overall, and by history of statin use prior to their index MI hospitalization. Beneficiaries who reinitiated high-intensity statins were less likely to have Relative risks are adjusted for demographics (ie, age, race/ethnicity, sex, low-income subsidy, area-level median income, geographic region), characteristics prior to the myocardial infarction hospitalization (ie, cardiologist care, diabetes mellitus, stroke, chronic kidney disease, heart failure, coronary heart disease, status of statin use, and nonstatin lipid-lowering medication use), and characteristics during the MI hospitalization (length of hospitalization, coronary stent insertion, newly diagnosed heart failure, diabetes mellitus, and chronic kidney disease) and statin intolerance within 182 days after the myocardial infarction hospital discharge. CI indicates confidence interval; and RR, relative risk.
*Last statin intensity prior to discontinuation or 182 days after hospital discharge: For beneficiaries who discontinued statin use, the last statin intensity filled prior to the ≥60-day continuous gap in statin therapy (ie, no days' supply). For beneficiaries who did not discontinue (ie, reference group), the last statin intensity filled prior to 182 days post-discharge for the index myocardial infarction.
†Statin discontinuation was defined as a ≥60-day continuous gap in statin therapy (ie, no days' supply). Patterns of Statin Utilization high statin persistence than beneficiaries who reinitiated lowintensity statins, but no association was present for those reinitiating a moderate-versus low-intensity statin. Down-titration of statin intensity upon reinitiation was associated with higher statin persistence compared with reinitiating the same intensity, but no association with up-titration was present. Also, reinitiating a different compared with the same statin drug type was associated with higher persistence. These results were consistent for beneficiaries without and with a history of statin use.
Beneficiary Characteristics and Statin Discontinuation, Statin Reinitiation, and High Statin Persistence
Being male, having a low-income subsidy, higher area-level median income, region of residence, and statin use prior to the index MI event and coronary stent insertion were associated with a lower likelihood of discontinuation (Table V in the Data  Supplement) . Having a race/ethnicity other than non-Hispanic white, cardiologist care prior to MI hospitalization, diabetes mellitus, history of CKD, HF, CHD, and statin intolerance were associated with a higher probability of discontinuation.
Older age, low-income subsidy, history of HF, and statin intolerance were associated with less statin reinitiation ( High statin persistence was more common among beneficiaries with area-level median income in the upper half, those with a history of statin and nonstatin lipid-lowering medication use prior to their MI hospitalization and hospitalized for ≥5 days, and newly diagnosed HF during MI hospitalization.
Discussion
Of the 158 795 Medicare beneficiaries discharged for a MI and who filled statins within 30 days in the current analysis, 15.4% discontinued treatment within 182 days of discharge. Statin reinitiation occurred within 365 days among 53.7% of beneficiaries who discontinued treatment, 27.1% changed statin type, 6.9% up-titrated, 14.4% down-titrated, and 66.0% reinitiated the same statin drug and intensity. Among those who reinitiated statin therapy, 45.8% had high statin persistence over the next 182 days. Beneficiaries who did not have a history of statin use prior to their MI hospitalization were more likely to discontinue statins and less likely to reinitiate treatment and be highly persistent after reinitiation. High statin persistence after reinitiation was less common among beneficiaries who filled high-intensity statins and more common in those who downtitrated and changed statin type on reinitiation.
Statins are a class 1A approach for secondary prevention in patients with history of MI. 4 The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommends initiating highintensity statin therapy after a MI among people ≤75 years of age to achieve an ≈50% reduction in low-density lipoprotein Relative risks are adjusted for demographics (ie, age, race/ethnicity, sex, low income subsidy, area-level median income, geographic region), characteristics prior to the myocardial infarction hospitalization (ie, cardiologist care, diabetes mellitus, stroke, chronic kidney disease, heart failure, coronary heart disease, status of statin use, and nonstatin lipid-lowering medication use), and characteristics during the MI hospitalization (length of hospitalization, coronary stent insertion, newly diagnosed heart failure, diabetes mellitus, and chronic kidney disease) and statin intolerance within 182 days after statin reinitiation.
*High statin persistence was defined as a proportion of days covered ≥80% during the 182 days after reinitiation and having at least 1 day supply of statin on day 182 after reinitiation.
†Statin reinitiation was defined as a statin fill in the 365 days after the date of statin discontinuation. Patterns of Statin Utilization cholesterol. 4 Moderate-intensity statin therapy is recommended for secondary prevention in most individuals over 75 years of age. These guidelines are based on consistent evidence from randomized controlled trials, indicating that statin-related risk reductions are between 20% and 30%.
14 The benefits of statins accumulate from continuation of therapy, but patients frequently discontinue this medication.
While 15% to 75% of patients have been reported to discontinue statins in observational studies, the wide range in percentage discontinuation may be attributed to the variable definitions between studies. [15] [16] [17] Prior studies have required 15-to 360-day treatment gaps, with higher discontinuation rates being reported for shorter versus longer breaks in treatment. 17 Further, discontinuation rates may be influenced by whether prior studies carried statin pills remaining from a fill prior to hospital admission into the time period post-discharge and whether an existing statin supply was augmented by the new statin fill. 17 In the current study, we defined discontinuation as a 60-day treatment gap during 182 days after hospital discharge for a MI, which is a stringent definition that potentially explains why the observed discontinuation rate was at the lower end of the range from previous reports. 18, 19 Statin discontinuation occurs for numerous reasons. One of the most common is muscle-related symptoms, which affect ≤25% of patients. 20 However, statin-associated symptoms do not always recur with statin reinitiation. Among participants with a history of statin intolerance in the GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3) randomized controlled trial, 43% had intolerable muscle-related symptoms on atorvastatin but not placebo, 27% had intolerable muscle-related symptoms on placebo but not atorvastatin, 10% had intolerable muscle-related symptoms on both atorvastatin and placebo, and 17% had no intolerable symptoms on either therapy. 21 This suggests that even among patients with a history of statin intolerance, some are able to successfully reinitiate statins. Restarting statin therapy can substantially lower low-density lipoprotein cholesterol levels, providing benefit by reducing cardiovascular disease risk. 21 Studies of healthcare utilization databases from Europe and Canada in the 1990s indicate that ≈50% of patients attempted and successfully reinitiated statin medication within 6 to 12 months after discontinuation. 7, 8 This is substantially lower compared with more recent studies. 10, 21 Using data from the Clinical Practice Research Datalink in the United Kingdom, among the 41% of secondary prevention patients who discontinued treatment for 90 days, 75% reinitiated the medication. 10 The current study provides evidence that, similar to the European and Canadian studies, there remains a significant proportion of Medicare beneficiaries with history of MI who do not reinitiate statins.
Few studies have assessed statin persistence after reinitiation. In routine care settings affiliated with Brigham and Women's Hospital and Massachusetts General Hospital, 92.2% of primary and secondary prevention patients who discontinued and reinitiated statins were taking statins a year after side-effect symptoms related to their statin use (eg, myopathy, rhabdomyolysis). 22 In the current study, only 45.8% of Medicare beneficiaries with a history of MI who discontinued statins, a subgroup with high cardiovascular disease risk, had high statin persistence for 182 days after reinitiation. However, changing statin drug and down-titration were associated with higher persistence. Although high-intensity statins that reduce low-density lipoprotein cholesterol by ≈50% are preferred for many individuals with a history of MI, lower-intensity statins that result in smaller low-density lipoprotein cholesterol reductions are recommended for individuals over 75 years of age and individuals who cannot tolerate high-intensity statins or have contraindications to high-intensity statins. 4 Intermittent statin dosing may be prescribed for statin-intolerant patients. Combination of lipid-lowering therapy may also be useful for some individuals who do not have sufficient low-density lipoprotein cholesterol reduction with maximally tolerated statins. 23, 24 Because higher risk patients tend to have a greater absolute risk reduction with statin therapy, 25, 26 the reasons why more than half of Medicare beneficiaries do not persist on statin therapy after reinitiation warrants further research.
The current study has several strengths. A large, national sample of older US adults was included. Thus, the results reported herein are highly generalizable. Also, the analytic population was large enough to evaluate statin use patterns in beneficiaries with and without a history of statin use prior to a MI hospitalization. The results should be interpreted in the context of several limitations. There was no information available for beneficiaries who filled statin prescriptions without submitting a claim (eg, cash payments), but prior studies suggest that this occurs for a low percentage of Medicare beneficiaries. 27, 28 Also, an underlying assumption was that beneficiaries had daily statin dosing. Those who were prescribed a regimen of taking statins every other day or 1 to 2 pills per week would be categorized as being nonpersistent. Further, those who died during follow-up and who did not have full fee-for-service coverage were not included in the current analyses. Last, laboratory values were not available, precluding analyses of low-density lipoprotein cholesterol values.
In conclusion, almost 1 in 6 Medicare beneficiaries who initiated statins within 30 days after MI hospitalization discontinued treatment for at least 60 days in the 182 days postdischarge. Although more than half of the beneficiaries who discontinued statins reinitiated treatment, less than half of these individuals had high persistence for 182 days after reinitiation. Reinitiating therapy with moderate-or low-intensity statins, down-titration, and changing statins may promote persistence in older adults who discontinue statins after a MI hospitalization. These data demonstrate the need to implement interventions aimed at increasing long-term statin use in patients hospitalized for a MI.
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